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Abstract
AIM
To characterize peripheral blood natural killer (NK) cells 
phenotypes by flow cytometry as potential biomarker 
of liver fibrosis in human immunodeficiency virus (HIV)/
hepatitis C virus (HCV) coinfected patients.
METHODS
Peripheral mononuclear cells from 24 HIV/HCV (HBV 
Submit a Manuscript: http://www.f6publishing.com
DOI: 10.4254/wjh.v9.i25.1073
World J Hepatol  2017  September 8; 9(25): 1073-1080
ISSN 1948-5182 (online)
1074 September 8, 2017|Volume 9|Issue 25|WJH|www.wjgnet.com
Laufer N et al . CD4 T, NK cells and liver fibrosis
negative) coinfected and 5 HIV/HCV/HBV seronegative 
individuals were evaluated. HIV/HCV coinfected 
patients were divided in to groups: G1, patients with 
METAVIR F0-F2 and G2, patients with METAVIR F3-F4. 
NK surface cell staining was performed with: Anti-
CD3(APC/Cy7), anti-CD56(PE/Cy5), anti-CD57(APC), 
anti-CD25(PE), anti-CD69(FITC), anti-NKp30(PE), anti-
NKp46(PE/Cy7), anti-NKG2D(APC), anti-DNAM(FITC); 
anti-CD62L (PE/Cy7), anti-CCR7(PE), anti-TRAIL(PE), 
anti-FasL(PE), anti CD94(FITC). Flow cytometry data 
acquisition was performed on BD FACSCanto, analyzed 
using FlowJo software. Frequency of fluorescence was 
analyzed for all single markers.  Clinical records were 
reviewed, and epidemiological and clinical data were 
obtained.
RESULTS
Samples from 11 patients were included in G1 and from 
13 in G2. All patients were on ARV, with undetectable 
HIV viral load. Liver fibrosis was evaluated by transient 
elastography in 90% of the patients and with biopsy in 
10% of the patients. Mean HCV viral load was (6.18 ± 
0.7 log10). Even though, no major significant differences 
were observed between G1 and G2 regarding NK surface 
markers, it was found that patients with higher liver 
fibrosis presented statistically lower percentage of NK 
cells than individual with low to mild fibrosis and healthy 
controls (G2: 5.4% ± 2.3%, G1: 12.6% ± 8.2%, P  = 
0.002 and healthy controls 12.2% ± 2.7%, P = 0.008). 
It was also found that individuals with higher liver fibrosis 
presented lower CD4 LT count than those from G1 (G2: 
521 ± 312 cells/µL, G1: 770 ± 205 cells/µL; P = 0.035).
CONCLUSION
Higher levels of liver fibrosis were associated with lower 
percentage of NK cells and LTCD4+ count; and they 
may serve as noninvasive biomarkers of liver damage. 
Key words: CD4+ T cell; Human immunodeficiency 
virus/hepatitis C virus-coinfection; Fibrosis; Biomarker; 
Natural killer cells
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Approximately 2.3 million individuals with human 
immunodeficiency virus are coinfected with hepatitis C 
virus (HCV). The high cost of HCV treatment restricts its 
use. It is crucial to identify patients with advanced liver 
fibrosis with an urgent need of treatment. The aim of 
this study was to identify natural killer (NK) phenotypes 
as a biomarker for liver fibrosis. We observed that 
those subjects with higher fibrosis are those with lower 
percentage of NK cells and also with lower LTCD4+ count. 
These constitute two simple parameters that might be 
performed in a routine laboratory test and used in clinical 
practice as biomarkers for liver fibrosis.
Laufer N, Ojeda D, Polo ML, Martinez A, Pérez H, Turk G, Cahn 
P, Zwirner NW, Quarleri J. CD4+ T cells and natural killer cells: 
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INTRODUCTION
Chronic hepatitis C virus (HCV) infection affects 115 
million individuals worldwide and is a common cause 
of chronic hepatitis, which may eventually progress 
to cirrhosis and hepatocellular carcinoma[1]; whereas 
currently 36.9 million people are living with human 
immunodeficiency virus (HIV)/aids [2]. Because of 
overlapping pathways of transmission, approximately 
2.3 million individuals worldwide are estimated to be 
coinfected with both viruses[3]. Direct antiviral agents 
(DAA) are a major development in the treatment of 
HCV infection, with cure rates higher than 90%[4]. 
However, the high cost of DAA regimens and competing 
public health priorities have prompted a worldwide 
discussion whether all patients should have access 
to the new therapies without restriction. In many 
countries, new DAA regimens are therefore reserved 
for patients with advanced fibrosis or cirrhosis[5,6]. 
Liver fibrosis is a response to a wound-healing 
process triggered by various types of chronic liver 
injuries, among them HCV infection[7]. Liver fibrosis 
is well characterized by abnormal accumulation of 
extracellular matrix, and hepatic stellate cells (HSCs) 
are considered to be the major type of cells responsible 
for liver fibrosis. Such profibrotic role might be down-
regulated by natural killer (NK) cells either directly 
through induction of HSC apoptosis or indirectly via 
production of IFN-γ. Increased peripheral NK cell-
mediated cytotoxicity has been associated with less 
liver fibrosis during HCV infection and likely reflects 
this mechanism[7]. HIV infection per se has a strong 
suppressive effect on anti-HCV activity of NK cells[8].
NK cells are lymphoid cells that are primary re-
sponders to microbial infections and tumor cells[9]. 
Phenotypically, NK cells are defined as CD3-CD56+cells 
with variable expression of CD16, depending on cell 
subpopulation of NK cells. They comprise approxi-
mately 5%-20% of peripheral lymphoid cells, but up 
to 30%-50% of intrahepatic lymphoid cells. NK cell 
activation is regulated by cell surface receptors that 
become engaged by cognate ligands expressed on 
target cells by cytokines, and by Toll-like receptors 
(TLRs)[9-11]. 
Different techniques to asses liver fibrosis have 
been developed, from liver biopsy (gold standard) 
to non-invasive studies (transient liver elastography; 
patented and nonpatented biomarkers - FIB4, Fibro-
Test, APRI, etc). Liver biopsy is invasive and has risk of 
complications[12]. In addition, liver biopsy may be limited 
by the size of the specimen obtained as well as sampling, 
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intraobserver, and interobserver variability[13]. On the 
other hand, there are many unresolved issues regarding 
the accuracy (especially in HIV/HCV-coinfected 
patients) of noninvasive studies[14], and in low-resource 
countries there is an important barrier to access to 
these methods (in particular liver elastography and 
patented biomarkers). 
The identification of noninvasive liver fibrosis bio-
markers is still an open research area. In this context, 
we reasoned that the study of the phenotype of 
peripheral blood cells may unravel interesting clues 
towards the identification of such biomarkers. Some 
evidence indicates that the characteristics of the 
immune cells, including NK cells, observed in peripheral 
blood are similar to those seen in liver with relatively 
lower levels of magnitude. Accordingly, the aim of 
this study was to characterize peripheral blood NK cell 
phenotypes by flow cytometry as potential biomarker 
for liver fibrosis in patients chronically coinfected with 
hepatitis C and HIV.
MATERIALS AND METHODS
Study cohort
Informed consent was obtained from each subject. 
The study protocol is in line with the ethical guidelines 
of the Declaration of Helsinki and was approved by 
the ethics review committee of Fundación Huésped 
(Buenos Aires, Argentina).
Cryopreserved peripheral blood mononuclear cells 
(PBMC) from 24 HIV/HCV-coinfected individuals and 
5 HIV/HCV-seronegative individuals (healthy controls, 
HC) were used in this study. HIV/HCV-coinfected 
patients and healthy control individuals enrolled in this 
study were not acutely or chronically infected with 
HBV; they denied current use of recreational drugs 
or alcohol intake. HIV/HCV-coinfected patients were 
divided into two groups based on their level of liver 
fibrosis (group 1: Patients with METAVIR score F0 to 
F2 on liver biopsy or transient elastography - FibroScan®-; 
and group 2: Patients with METAVIR score F3-F4). 
Hepatic fibrosis was evaluated by liver biopsy in 10% of 
patients and by transient hepatic elastography in 90% 
of patients. All healthy control individuals presented 
F0-F1 fibrosis according to transient liver elastography 
(less than 5 kPa). Clinical records were reviewed, and 
epidemiological and clinical data were obtained.
Multicolor flow cytometry
Cryopreserved PBMC were thawed and stained with 
fluorochrome-conjugated antibodies distributed in 
five different panels (depending on PBMC availability) 
to evaluate expression of different markers on NK 
cells detailed in Table 1. Staining was performed for 
30 min at 4 ℃. Samples were washed, fixed in 1% 
paraformaldehyde and acquired in a FACS Canto flow 
cytometer (BD Biosciences). Data were analyzed using 
the FlowJo software (TreeStar, Ashland, Oregon, United 
States). NK cell populations were defined according to 
the corresponding isotype control.
Plasma viral load levels (Abbott RealTime HIV-1 
RNA version 3; Abbott Molecular, Inc., Des Plaines, IL, 
United States) were assessed in HIV-infected subjects 
and CD4+ T-cell counts (flow cytometry double 
platform, BD FACSCanto; BD Biosciences, San Diego/
California, United States) were assessed in HIV and 
HIV-negative individuals.
Statistical analysis
For categorical variables, both χ 2 and Fisher’s exact 
test were applied. For continuous variables, the 
nonparametric Kruskal-Wallis and Mann-Whitney test 
were used. Area under the receiving operating curve 
(ROC) was used to calculate the cut-off point in NK 
cell percentage with the best sensitivity of high liver 
fibrosis. Statistical analyses were performed using the 
Statistical Package for the Social Sciences software 
version 19.0 (SPSS Inc., Chicago, IL, United States).
RESULTS
Patient characteristics at the time of liver fibrosis 
assessment are shown in Table 2. Individuals from 
Group 1 (n = 11, 46%) presented low to mild liver 
fibrosis (METAVIR F0-F2) whereas patients included in 
Group 2 (n = 13, 54%) had severe fibrosis (METAVIR 
F3-F4). Forty percent of patients had previously 
received HCV treatment with pegylated interferon 
and ribavirin (with no differences between groups); a 
median of 6.25 ± 1.48 years before sample collection; 
none of them achieved sustained virological response. 
The mean age was 46.9 years (± 8.4); 83% were 
male. Patients from group 2 were older than those with 
lower METAVIR score (P = 0.028). No differences were 
Antibody Fluorochrome Clone Provider
All panels
   Anti-CD3 APC/Cy7 SK7 BioLegend
   Anti-CD56 PE/Cy5 679.1Mc7 Beckman Coulter
Panel 1
   Anti-CD57 APC HNK-1 BioLegend
   Anti-CD25 PE BC96 BioLegend
   Anti-CD69 FITC FN50 BioLegend
Panel 2
   Anti-NKp30 PE P30-15 Biolegend
   Anti-NKp46 PE/Cy7 9E2 Biolegend
   Anti-NKG2D APC 1D11 Biolegend
   Anti-DNAM FITC TX25 Biolegend
Panel 3
   Anti-CD62L PE/Cy7 DREG-56 Biolegend
   Anti-CCR7 PE G043H7 Biolegend
Panel  4
   Anti-TRAIL PE S35-934 BD Bioscience
Panel 5
   Anti-FasL PE NOK-1 Biolegend
   Anti CD94 FITC DX22 Biolegend
Table 1  Fluorochrome-conjugated antibodies panels
BioLegend, San Diego, California United States. BD Bioscience, San Jose, 
California, United States. NK: Natural killer.
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found between groups regarding gender or mean time 
of known HIV and HCV infection. The mean HCV viral 
load was 6.18 ± 0.70 log, with no differences between 
the two groups (G1: 6.54 ± 0.24; G2: 6.18 ± 0.7). 
HCV genotype 1 was identified in 90% of the patients, 
the rest presented infection by genotype 3. All patients 
were on antiretroviral treatment with undetectable 
HIV viral load, with no differences in the time on ARV 
therapy between groups. Patients with higher fibrosis 
presented lower CD4+ T cell count (521 ± 312 cells/µL) 
than those from group 1 (770 ± 205 cells/µL, P = 
0.035) There was no difference in the CD4+ T cell 
count between group 1 and healthy controls (P = 0.49).
Regarding NK cells, a lower percentage was found 
in samples from patients of group 2 (5.4% ± 2.3%) 
compared both with patients from group 1 (12.6% ± 
8.2%, P = 0.002) and healthy controls (12.2% ± 2.7%, 
0.008) (Figures 1 and 2). With ROC curve analysis 
a cut-off of a NK cell percentage lower than 6.6% 
was determined to have 90% sensitivity and 77% 
specificity to predict the presence of METAVIR F3-F4 
(Figure 3).
The percentage of CD56bright NK cells (G1: 11.7% 
± 8.0%, G2: 7.1% ± 4.0%, HC: 6.8% ± 3.6%) and 
CD56dim NK cells (G1: 88.2% ± 7.6%, G2: 73.7% ± 
40.1%, HC: 92.9% ± 3.6%) did not present differences 
among the three groups studied.
As the function of NK is regulated by an array of 
activating and inhibitory receptors, we also evaluated 
the NK cell activating receptors[15] NKp46 (CD335), 
NKp30 (CD337), NKG2D (CD314) and DNAM (CD226), 
the activation markers CD69 and CD25, and other 
molecules involved in NK cell effector functions, ter-
minal differentiation and cytotoxicity such as CD94, 
TRAIL, CD57[16], Fas-L (CD178), CCR7 (CD197) and 
CD62L.
When compared with healthy controls, samples from 
patients included in group 2 presented a higher frequency 
of CD56bright DNAM-1+ NK cells (76.2% ± 18.5% vs 4.6% 
± 8.5%, P = 0.008) and CD56dim DNAM-1+ NK cells 
(42% ± 29% vs 6.0% ± 8.1%, P = 0.018). The same 
differences were observed between group 1 and healthy 
controls, both in the percentage of CD56bright DNAM-1+ 
NK cells (71.2% ± 23% vs 4.6% ± 8.5%, P = 0.003) 
and in the percentage of CD56dim DNAM-1+ NK cells 
(41% ± 28% vs 6.0% ± 8.1%, P = 0.013).
Additionally, samples from group 1 exhibited higher 
percentage of CD56bright CD25+ NK cells (53.1% ± 
16.6% vs 19.4% ± 18.9%, P = 0.029) and CD56dim 
CD25+ NK cells (28.3% ± 10.2% vs 7.1% ± 5.6%, P 
= 0.001) than healthy controls. These results show the 
possible consequence of a higher activation degree in 
NK cells from subjects with chronic infection. Of note, 
there were no differences in the frequency of these 
NK cells subsets between group 1 and 2. Moreover, 
no differences were observed in the other activator 
molecules evaluated (NKp46, NKp30, NKG2D, CD69) 
neither between group 1 and 2 nor between controls 
and HCV-infected subjects.
No differences in surface expression of CD94 were 
observed between the 3 groups. The frequency of 
these molecules was very high in CD56bright NK cells in 
all the samples evaluated (G1: 77.1% ± 28.2%, G2: 
91.7% ± 1.2%, controls: 77.4% ± 36.7%), whereas 
in CD56dim NK cells this molecule was stained in less 
than 50% (G1: 48.4% ± 21.4%, G2: 36.9% ± 19.7%, 
controls: 31.6% ± 16.9%).
The frequency of CD56dim TRAIL+ NK cells was 
higher in samples from group 2 than those from group 
1 (29.4% ± 31.7% vs 7.5% ± 3.1%, P = 0.04), while 
no differences were observed between coinfected 
patients and healthy controls.
Nevertheless, the percentage of CD56dim FasL+ NK 
cells was lower in samples from HCV/HIV-coinfected 
patients (G1: 27.2% ± 19.8%, P = 0.001; G2: 36.9% 
± 19.7%, P = 0.01) than those from healthy controls 
(69.3% ± 18.2%), without detecting differences 
between groups 1 and 2.
In addition, there was a trend towards a higher 
percentage of CD56dim CCR7+ NK cells in samples from 
patients with advanced fibrosis than in samples from 
patients with lower fibrosis (G2: 56.4% ± 36.2% vs 
G1: 24.4% ± 14.6%; P = 0.05). Regarding the CD62L 
expression, there were no differences in CD56bright NK 
cells between groups (G1: 61.8% ± 24.9%; G2: 87% 
± 15.1%; P = 0.09).
DISCUSSION
In this study we found that patients with advanced 
fibrosis presented lower LT CD4+ cell counts than 
subjects with low to mild fibrosis. All the patients were 
on successful antiretroviral treatment. Even though 
there are controversial data whether the presence 
of HCV is a factor that alters LT CD4 recovery with 
ARV, it can be hypothesized that patients with higher 
chances to develop liver fibrosis are those with lower 
LT CD4+ cell recovery after HIV treatment. Such a 
poor HAART-mediated LT CD4+ cell recovery may 
Characteristics Group 1 Group 2 Control P  value
n  = 11 n  = 13 n  = 5
Age (yr)1 46.3 (3.9) 52.2 (4.5)  31 (4.8) 0.02
Male/female 9/2 11/2 3/2 0.85
CD4 cell count1   770 (205)   521 (312) 910 (251) 0.03
CD8 cell count1 1079 (475)   657 (339) NA 0.24
METAVIR F0-F2 100% 0 100% NC
METAVIR F3-F4 0 100% 0 NC
TGP1   79.7 (74.2)      99 (71.4) NA 0.41
Time of known HIV infection1      18 (6.52) 17.3 (3.8) NC 0.60
Time of known HCV infection1 14.3 (7.0) 13.8 (4.6) NC 0.65
Table 2  Characteristics of the population and divided 
according the level of fibrosis
1mean ± SD. Beckman Coulter, Marseille, France. P values, correspond to 
comparison between group 1 and 2. NA: Not available; NC: Not correspond; 
HIV: Human immunodeficiency virus; HCV: Hepatitis C virus.
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contribute to an impaired stimulation of NK cells, 
and consequently a diminished anti-fibrotic activity 
by their action on hepatic stellate cells, favoring an 
accelerated liver fibrosis progression in HIV/HCV 
patients[17]. Yi et al[18] and other groups have observed 
that NK cells negatively regulated liver fibrosis. NK 
cells isolated from HCV-infected patients efficiently 
induced apoptosis of activated HSCs in TRAIL-, FasL-, 
and NKG2D-dependent manners[19]. NKp46high NK cell 
subset potentially suppresses HCV replication and HCV-
associated liver damage, leading to amelioration of liver 
fibrosis.
It has been described that HIV/HCV coinfection 
can modulate the peripheral NK phenotype[20]. In 
our study, we also observed differences in the NK 
phenotype particularly between control and HIV/HCV-
coinfected patients which resemble those reported 
previously[21,22]. We found a lower percentage of 
CD56dim FasL+ NK cells in HCV/HIV-coinfected patients 
compared to healthy controls. This finding could reflect 
a lower NK cell capacity to exert cytotoxic activity in 
patients with chronic HIV and HCV infection compared 
to non-infected individuals that could ultimately lead to 
a decreased capacity to regulate HSC.
Regarding HIV/HCV-coinfected individuals, no 
differences were observed in NK cell phenotypes 
according to the different degrees of liver fibrosis. 
Nevertheless, we could observe a statistically sig-
nificant difference in the percentage of peripheral 
1500
1000
500
0
LT
 C
D
4+
 (
ce
lls
/ µ
L)
Control           G1              G2
P  = 0.49
P  = 0.035
40
30
20
10
0
%
 N
K
Control           G1              G2
P  = 0.008
P  = 0.002 80
60
40
20
0
%
 N
K 
CD
56
br
ig
ht
 C
D
25
+
Control           G1              G2
P  = 0.02
60
40
20
0
%
 N
K 
CD
56
di
m
 C
D
25
+
Control           G1              G2
P  = 0.001 100
50
0
-50%
 N
K 
CD
56
br
ig
ht
 D
N
AM
Control           G1              G2
P  = 0.003
P  = 0.008
100
80
60
40
20
0
%
 N
K 
CD
56
di
m
 D
N
AM
Control           G1              G2
P  = 0.018
150
100
50
0
%
 N
K 
CD
56
di
m
 C
CR
7+
Control           G1              G2
P  = 0.05 100
80
60
40
20
0
%
 N
K 
CD
56
di
m
 T
RA
IL
Control           G1              G2
P  = 0.04 150
100
50
0
%
 N
K 
CD
56
di
m
 F
AS
L
Control           G1              G2
P  = 0.02
P  = 0.006
A B C
D E F
G H I
Figure 2  Differences between groups 1, 2 and controls regarding. A: Total CD4 cell count; B: Percent of NK cells; C: Percent NK CD56bright CD25+; D: Percent 
CD56dim CD25+ NK cells; E: Percent CD56bright DNAM+ NK cells; F: Percent CD56dim DNAM+ NK cells; G: Percent CD56dim CCR7+ NK cells; H: Percent CD56dim TRAIL+ NK 
cells; I: Percent CD56dim FasL+ NK cells. The P values are shown in each graphic and the line below the P value connects the two groups compared. NK: Natural killer.
Natural killer
100
80
60
40
20
0
Se
ns
iti
vi
ty
0          20         40         60         80        100
100-specificity
Figure 3  Area under the receiver operating characteristic curve, to evaluate 
the performance of natural killer cell % with liver fibrosis as the state variable.
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blood NK cells in patients with high scores compared to 
patients with low liver fibrosis. Patients with advanced 
fibrosis have lower percentage of NK cells than those 
with low fibrosis scores. Moreover, we observed that 
a percentage of NK cells lower than 6.6% had 90% 
sensitivity and 77% specificity to predict the presence 
of advance fibrosis (METAVIR F3-F4). This observation 
could indicate, for the first time, that the evaluation of 
the NK cells compartment is a potential biomarker for 
fibrosis staging in HIV/HCV-coinfected patients. 
In the era of direct antiviral agents with high efficacy 
for the treatment of chronic HCV, one of the main treat-
ment access barriers for many patients is the high 
cost of these drugs, and where these barriers exist the 
assessment of liver fibrosis is mandatory to ensure 
treatment access. In this study, we have observed 
that those subjects with higher fibrosis are those 
with lower absolute count both of LT CD4+ and lower 
percentage of NK cells. Although additional research 
is needed to confirm our findings, the evaluation of 
these two parameters that can be performed in a 
routine laboratory test may be helpful in improving the 
available noninvasive methods for liver fibrosis staging. 
COMMENTS
Background
Different techniques to assess liver fibrosis have been developed, from liver 
biopsy (gold standard) to non-invasive studies (transient liver elastography; 
patented and non-patented biomarkers - FIB4, FibroTest, APRI, etc). Liver 
biopsy is invasive and has risk of complications. In addition, liver biopsy may 
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regarding the accuracy [especially in human immunodeficiency virus (HIV)/ 
hepatitis C virus (HCV)-coinfected patients] of noninvasive studies, and in low-
resource countries there is an important barrier to access to these methods (in 
particular liver elastography and patented biomarkers).
Research frontiers
The identification of non-invasive liver fibrosis biomarkers is still an open 
research area. In this context, the authors reasoned that the study of the 
phenotype of peripheral blood cells may unravel interesting clues towards 
the identification of such biomarkers. Some evidence indicates that the 
characteristics of the immune cells, including natural killer (NK) cells, observed 
in peripheral blood are similar to those seen in liver with relatively lower levels 
of magnitude. Accordingly, the aim of this study was to characterize peripheral 
blood NK cell phenotypes by flow cytometry as potential biomarker for liver 
fibrosis in patients chronically coinfected with hepatitis C and HIV.
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In the era of direct antiviral agents with high efficacy for the treatment of chronic 
HCV, one of the main treatment access barriers for many patients is the high 
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fibrosis is mandatory to ensure treatment access. In this study, the authors have 
observed that those subjects with higher fibrosis are those with lower absolute 
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research is needed to confirm their findings, the evaluation of these two 
parameters that can be performed in a routine laboratory test may be helpful in 
improving the available noninvasive methods for liver fibrosis staging.
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The data in this study suggested that LTCD4 and NK cells could be used 
as potential non-invasive biomarkers of the level of liver fibrosis in HIV-HCV 
coinfected patients. These parameters could improve the accuracy of the 
available non-invasive methods to measure liver fibrosis.  
Terminology
NK cells, and CD4 T lymphocytes (LTCD4) are involved in the immunological 
control of hepatic stellate cells that are the responsible of liver fibrosis 
development. 
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The identification of noninvasive liver fibrosis biomarkers is still an open 
research area. NK cells and LTCD4+ count; are two simple parameters, that 
might be perform in a routine laboratory test and may serve as noninvasive 
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